A joint analysis of two important phase III clinical trials TEXT Tamoxifen and Exemestane Trial and SOFT Suppression of Ovarian Function Trial showed that exemestane plus ovarian function suppression was superior to tamoxifen plus ovarian suppression in preventing recurrence in premenopausal women with hormone sensitive breast cancers arimidex vs nolvadex